A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2002
12/04/2002	EP1261369A2 Compositions and methods for tumor-targeted delivery of effector molecules
12/04/2002	EP1261366A1 Adjuvant treatment by in vivo activation of dendritic cells
12/04/2002	EP1261364A1 Method of treating or inhibiting cellular injury or cell death
12/04/2002	EP1261363A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
12/04/2002	EP1261361A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1
12/04/2002	EP1261357A1 Isolation and transplantation of retinal stem cells
12/04/2002	EP1261355A1 Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
12/04/2002	EP1261348A2 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
12/04/2002	EP1261347A1 Therapeutic compositions and methods for treatingperiodontitis with antiinflamatory compounds
12/04/2002	EP1261343A2 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
12/04/2002	EP1261342A2 Farnesyl protein transferase inhibitor combinations
12/04/2002	EP1261339A1 Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
12/04/2002	EP1261337A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
12/04/2002	EP1261335A1 Brain, spinal and nerve injury treatment
12/04/2002	EP1261334A1 Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
12/04/2002	EP1261332A1 Use of cyp1b1 inhibitors for treating cancer
12/04/2002	EP1261331A1 Method and compositions for treating fibrotic diseases
12/04/2002	EP1261324A2 Tramadol for the treatment of functional gastrointestinal disorders
12/04/2002	EP1261323A2 Method of treating gastrointestinal tract disease with purinergic receptor agonists
12/04/2002	EP1261322A2 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
12/04/2002	EP1261320A2 Micellar pharmaceutical compositions for buccal and pulmonary application
12/04/2002	EP1261317A2 Methods and compositions for treating and preventing posterior segment ophthalmic disorders
12/04/2002	EP1261310A1 Cosmetic and pharmaceutical preparations for treating cellulite
12/04/2002	EP1180026B1 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
12/04/2002	EP1146878A4 Biochemical compositions used in human treatment
12/04/2002	EP0925060B1 Fast decomposing pellets
12/04/2002	EP0850046B1 Microemulsions for use as vehicles for administration of active compounds
12/04/2002	EP0820306B1 Pharmaceutical composition containing pectin and a phospholipid, used as an antidiarrheal and antiulcer agent
12/04/2002	EP0814837B1 Use of g class immunoglobulins for the topical treatment of atopic dermatitis
12/04/2002	CN1383452A Compsns. and methods for treating cells having double minute DNA
12/04/2002	CN1383375A Treatment of human herpesviruses using hyperthermia
12/04/2002	CN1382490A Treatment application of selectivity PDE10 suppressant
12/04/2002	CN1382450A Stem cell medicine for repairing damage of central nerve and its preparing process
12/04/2002	CN1382442A Method for preventing dyskinesia
12/04/2002	CN1382440A Method and medicine case for treating depression or preventing degeneration of cognitive function
12/04/2002	CA2384907A1 Methods and compositions relating to mek5 and cardiac hypertrophy and dilated cardiomyopathy
12/03/2002	US6489535 Non-mammalian transgenic animal having an adult onset neurodegenerative phenotype
12/03/2002	US6489478 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
12/03/2002	US6489448 Antibody to a protein with thiol specific antioxidant (tsa) activity; vaccines
12/03/2002	US6489369 Insoluble or sparingly water soluble drugs such as etoposide, paclitaxel, propofol or cyclosporins, biodegradable/ -compatible sterol solubilizers, carriers and diluents having storage stability
12/03/2002	US6489366 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
12/03/2002	US6489346 Substituted benzimidazole dosage forms and method of using same
12/03/2002	US6489345 Treating diabetes mellitus in a mammal comprising administering a therapeutically effective amount of a 3-acylated pyricoxal analogue or a pharmaceutically acceptable acid addition salt thereof
12/03/2002	US6489330 Or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of such as famciclovir; prophylactic treatment for kaposi's sarcoma or aids related disease
12/03/2002	US6489319 Psychological disorders; cognition activators
12/03/2002	US6489317 An ansamycin, at least one second antimicrobial agent selected from amoxycillin, tetracycline and bismuth compounds, and a proton pump inhibitor
12/03/2002	US6489307 Reducing the level of transcription of beta 1-adrenoceptor polypeptide-specific mrna in a mammalian host cell, by administering oligonucleotide; reduces receptor expression; hypotensive effect
12/03/2002	US6489302 Of varous drugs (such as anticancer agents) that make use of glucose transporter to deliver drugs to site of action (such as across blood-brain barrier) more efficiently, thereby reducing side effects
12/03/2002	US6489137 For use in cancer diagnostics; detection of the loss and or alteration of wild-type hubub1 genes in tumor tissues
12/03/2002	US6489130 Death associated kinase containing ankyrin repeats (DAKAR)
12/03/2002	US6489128 Methods for detecting cancer of the central nervous system
12/03/2002	US6488969 Method for reducing blood ammonia concentration
12/03/2002	US6488968 For increasing bioavailability of phytoestrogens comprising effective amounts of a phytoestrogen, a dietary fiber and l-glutamine
12/03/2002	US6488967 Gastric acid secretion
12/03/2002	US6488943 Anionic surfactant; proton donating agent comprising 2-pyrrolidone-5 carboxylic acid
12/03/2002	US6488927 Fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
12/03/2002	CA2228249C Pain-alleviating drug composition and method for alleviating pain
12/03/2002	CA2213198C Gene therapy by anti-tgf-b agents
12/03/2002	CA2092914C Synergism of tnf and il-4
12/03/2002	CA2042668C Treatment of amyloidosis associated with alzheimer's disease
11/2002
11/30/2002	CA2389560A1 Cosmetic and/or dermatological and/or pharmaceutical compound for topical application, containing at least one 3 beta-hydroxysteroid dehydrogenase enzyme inhibitor
11/30/2002	CA2387699A1 Combination treatment for sleep disorders including sleep apnea
11/30/2002	CA2349135A1 Therapies for the prevention and treatment of diabetes and obesity
11/28/2002	WO2002095704A1 Use of nf-kappa-b inhibitors to treat dry eye disorders
11/28/2002	WO2002095393A2 Drug evolution: drug design at hot spots
11/28/2002	WO2002095391A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002	WO2002095036A2 A novel intein and uses thereof
11/28/2002	WO2002095034A2 A retinoic acid metabolizing cytochrome p450
11/28/2002	WO2002095015A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
11/28/2002	WO2002095007A2 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	WO2002095005A2 Therapeutic dna vaccination
11/28/2002	WO2002094990A2 Receptors and membrane-associated proteins
11/28/2002	WO2002094876A2 Methods and compositions for treating respiratory mucin production associated disease conditions
11/28/2002	WO2002094874A2 Internalisation of virus into cells
11/28/2002	WO2002094864A2 Human cdnas and proteins and uses thereof
11/28/2002	WO2002094856A2 Gpe analogs and peptidomimetics
11/28/2002	WO2002094833A1 Novel pyrrole derivatives as pharmaceutical agents
11/28/2002	WO2002094830A2 DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
11/28/2002	WO2002094823A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
11/28/2002	WO2002094813A1 Novel pyridyl cyanoguanidine compounds
11/28/2002	WO2002094780A2 Kinases and phosphatases
11/28/2002	WO2002094745A2 Non-peptidic cyclophilin binding compounds and their use
11/28/2002	WO2002094744A2 Compositions comprising d-chiro inositol and sulfonylureas and methods of treatment thereof
11/28/2002	WO2002094379A1 Use and compositions of antiprogestins for treatment of prostate diseases
11/28/2002	WO2002094377A2 Pharmaceutical preparation comprising physiologically acceptable potassium and magnesium salts and use thereof for the prophylaxis and treatment of qt-interval extension
11/28/2002	WO2002094368A1 Transdermal drug delivery devices having coated microprotrusions
11/28/2002	WO2002094322A2 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug
11/28/2002	WO2002094317A1 Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists
11/28/2002	WO2002094311A1 Use of proteasome inhibitors to treat dry eye disorders
11/28/2002	WO2002094283A2 Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs
11/28/2002	WO2002094278A1 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
11/28/2002	WO2002094276A1 Pharmaceutical composition for use in hormone replacement therapy
11/28/2002	WO2002094275A1 Use of estrogen compounds to increase libido in women
11/28/2002	WO2002094273A2 Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
11/28/2002	WO2002094272A1 Analgesic composition and method
11/28/2002	WO2002094271A1 Targeted delivery of bioaffecting compounds for the treatment of cancer
11/28/2002	WO2002094254A2 Abuse resistant pharmaceutical composition containing capsaicin
11/28/2002	WO2002094251A1 Compositions for the treatment of pigmentation disorders and methods for their manufacture
11/28/2002	WO2002094236A1 Delivery of antipsychotics through an inhalation route
11/28/2002	WO2002094227A1 Controlled release drug delivery device

1 ... 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 ... 1151